[go: up one dir, main page]

NI201900005A - Anticuerpos anti-gprc5d, molã‰culas de uniã“n a antãgeno bispecãfico que unen a gprc5d y cd3, y sus usos - Google Patents

Anticuerpos anti-gprc5d, molã‰culas de uniã“n a antãgeno bispecãfico que unen a gprc5d y cd3, y sus usos

Info

Publication number
NI201900005A
NI201900005A NI201900005A NI201900005A NI201900005A NI 201900005 A NI201900005 A NI 201900005A NI 201900005 A NI201900005 A NI 201900005A NI 201900005 A NI201900005 A NI 201900005A NI 201900005 A NI201900005 A NI 201900005A
Authority
NI
Nicaragua
Prior art keywords
gprc5d
antibodies
binding
antigen
cancer
Prior art date
Application number
NI201900005A
Other languages
English (en)
Inventor
Attar Ricardo
Chin Diana
Edavettal Suzanne
Gaudet François
Li Yingzhe
Luistro Leopoldo
Majewski Nathan
Mendonca Mark
Pillarisetti Kondandaram
Teplayakov Alexey
Tornetta Mark
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201900005A publication Critical patent/NI201900005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En este documento se proporcionan anticuerpos que se unen específicamente a GPRC5D. También se describen polinucleótidos relacionados capaces de codificar los anticuerpos específicos para GPRC5D proporcionados o fragmentos de unión a antígeno, células que expresan los anticuerpos proporcionados o fragmentos de unión a antígeno, así como vectores asociados y anticuerpos marcados de forma detectable o fragmentos de unión a antígeno. Además, se describen los métodos de uso de los anticuerpos proporcionados. Por ejemplo, los anticuerpos provistos pueden usarse para diagnosticar, tratar o monitorear la progresión, regresión o estabilidad del cáncer que expresa GPRC5D; para determinar si un paciente debe o no ser tratado por cáncer; o para determinar si un sujeto está o no afectado con cáncer que expresa GPRC5D y, por lo tanto, puede ser susceptible de tratamiento con un agente terapéutico contra el cáncer específico para GPRC5D, como los anticuerpos multiespecíficos contra GPRC5D y CD3 descritos en el presente documento.
NI201900005A 2016-07-20 2019-01-18 Anticuerpos anti-gprc5d, molã‰culas de uniã“n a antãgeno bispecãfico que unen a gprc5d y cd3, y sus usos NI201900005A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662364811P 2016-07-20 2016-07-20

Publications (1)

Publication Number Publication Date
NI201900005A true NI201900005A (es) 2019-05-10

Family

ID=60992891

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900005A NI201900005A (es) 2016-07-20 2019-01-18 Anticuerpos anti-gprc5d, molã‰culas de uniã“n a antãgeno bispecãfico que unen a gprc5d y cd3, y sus usos

Country Status (38)

Country Link
US (4) US10562968B2 (es)
EP (2) EP3487882B1 (es)
JP (3) JP7292200B2 (es)
KR (3) KR20250073578A (es)
CN (2) CN109715667B (es)
AR (4) AR109499A1 (es)
AU (2) AU2017299673B2 (es)
BR (1) BR112019001055A2 (es)
CA (1) CA3031472A1 (es)
CL (4) CL2019000146A1 (es)
CO (1) CO2019001114A2 (es)
CR (1) CR20190025A (es)
DK (1) DK3487882T3 (es)
EA (1) EA201990346A1 (es)
EC (1) ECSP19012075A (es)
ES (1) ES3042078T3 (es)
FI (2) FI3487882T3 (es)
HR (1) HRP20251181T1 (es)
HU (1) HUE073077T2 (es)
IL (2) IL298277A (es)
IN (1) IN201917002488A (es)
LT (2) LT3487882T (es)
MA (1) MA45712B1 (es)
MX (3) MX2019000825A (es)
NI (1) NI201900005A (es)
NZ (2) NZ790480A (es)
PE (2) PE20190392A1 (es)
PH (1) PH12019500152A1 (es)
PL (1) PL3487882T3 (es)
PT (1) PT3487882T (es)
RS (1) RS67235B1 (es)
SG (1) SG11201900468YA (es)
SI (1) SI3487882T1 (es)
SM (1) SMT202500356T1 (es)
TW (1) TWI781108B (es)
UY (5) UY40768A (es)
WO (1) WO2018017786A2 (es)
ZA (1) ZA201901066B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
TW201837174A (zh) * 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
KR20220080044A (ko) * 2018-05-16 2022-06-14 얀센 바이오테크 인코포레이티드 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체
CN111116753A (zh) * 2018-10-30 2020-05-08 上海泰因生物技术有限公司 一种双特异性抗体的制备方法
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
KR20210099614A (ko) * 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
TWI861039B (zh) * 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
EP3911677A1 (en) * 2019-01-18 2021-11-24 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
EP3994270A1 (en) 2019-07-02 2022-05-11 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
JP2022543553A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
WO2021018925A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
KR20220122656A (ko) * 2019-12-06 2022-09-02 주노 쎄러퓨티크스 인코퍼레이티드 Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
JP7285495B2 (ja) * 2020-03-30 2023-06-02 国立大学法人三重大学 二重特異的抗体
CA3189562A1 (en) * 2020-07-17 2022-01-20 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-gprc5d antibodies
CA3194796A1 (en) 2020-09-16 2022-03-24 Janssen Biotech, Inc. Methods for treating multiple myeloma
CN116574184A (zh) * 2021-01-05 2023-08-11 上海礼新医药研发有限公司 抗gprc5d单克隆抗体及其用途
WO2022148370A1 (en) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anti-gprc5d monoclonal antibodies and uses thereof
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
JP2024510098A (ja) * 2021-02-19 2024-03-06 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用
US12103977B2 (en) 2021-03-24 2024-10-01 Janssen Biotech, Inc. Trispecific antibody targeting CD79b, CD20, and CD3
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
WO2022247804A1 (zh) * 2021-05-23 2022-12-01 上海祥耀生物科技有限责任公司 抗gprc5d抗体、其制备方法与用途
MX2024005406A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
WO2023078382A1 (zh) 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 结合gprc5d的抗体及其用途
WO2023173272A1 (zh) * 2022-03-15 2023-09-21 上海驯鹿生物技术有限公司 靶向gprc5d的全人源嵌合抗原受体(car)及其应用
KR20240125026A (ko) * 2021-12-21 2024-08-19 상하이 이아소 바이오테크놀로지 씨오., 엘티디. Gprc5d를 표적으로 하는 완전 인간 항체와 키메라 항원 수용체(car) 및 이의 용도
WO2023115347A1 (zh) * 2021-12-21 2023-06-29 上海驯鹿生物技术有限公司 靶向gprc5d的全人源抗体
CN116375867A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 抗gprc5d抗体及其应用
WO2023125888A1 (zh) * 2021-12-31 2023-07-06 山东先声生物制药有限公司 一种gprc5d抗体及其应用
WO2023125729A1 (zh) * 2021-12-31 2023-07-06 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
US20250092135A1 (en) 2022-01-10 2025-03-20 Nanjing Leads Biolabs Co., Ltd. Antibody and use thereof
JP2025508343A (ja) * 2022-01-29 2025-03-26 ▲かい▼興生命科技（上海）有限公司 Ｇｐｒｃ５ｄ抗体及びその使用
MX2024011128A (es) * 2022-03-14 2024-09-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
CA3247475A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS
AU2023275810A1 (en) * 2022-05-27 2024-12-12 Antengene Biologics Limited Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
WO2023236889A1 (zh) * 2022-06-06 2023-12-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
WO2024002308A1 (zh) 2022-06-30 2024-01-04 康诺亚生物医药科技（成都）有限公司 一种新型多特异肿瘤抑制剂的开发和应用
WO2024017326A1 (zh) * 2022-07-21 2024-01-25 山东先声生物制药有限公司 抗gprc5d纳米抗体及其应用
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
CN116003598B (zh) 2022-08-30 2024-04-26 苏州缔码生物科技有限公司 靶向人gprc5d的重组人源化单克隆抗体及其应用
AU2023334858A1 (en) 2022-09-01 2025-03-20 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
KR20250057914A (ko) * 2022-09-09 2025-04-29 베이징 맵웍스 바이오테크 컴퍼니 리미티드 다중-특이적 항체 결합 bcma, gprc5d 및 cd3 및 이의 용도
TW202430211A (zh) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
KR20250123204A (ko) * 2022-12-22 2025-08-14 얀센 파마슈티카 엔브이 항체-폴리뉴클레오티드 접합체의 제조 방법
TW202434644A (zh) 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 三特異性抗原結合分子及其應用
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
US20240392027A1 (en) 2023-02-28 2024-11-28 Janssen Biotech Inc. Compositions comprising a bispecific gprc5d/cd3 antibody
CN120882747A (zh) * 2023-03-22 2025-10-31 百放英库医药科技(北京)有限公司 一种抗gprc5d纳米抗体及其应用
AU2024260168A1 (en) * 2023-04-28 2025-12-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody targeting g protein-coupled receptor
TW202446793A (zh) * 2023-05-16 2024-12-01 大陸商上海齊魯製藥研究中心有限公司 雙特異性抗原結合分子及其應用
WO2024246856A1 (en) 2023-06-01 2024-12-05 Janssen Biotech, Inc. Methods for treating multiple myeloma
AU2024283895A1 (en) 2023-06-06 2025-12-18 Fortvita Biologics Inc. Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
CN120129703A (zh) * 2023-06-09 2025-06-10 德琪(杭州)生物有限公司 靶向cd3和另一靶点的新颖抗体及其用途
TW202500590A (zh) * 2023-06-28 2025-01-01 大陸商浙江博銳生物製藥有限公司 抗ｇｐｒｃ５ｄ抗體及其醫藥用途
WO2025019733A2 (en) * 2023-07-20 2025-01-23 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025056013A1 (zh) * 2023-09-13 2025-03-20 江苏恒瑞医药股份有限公司 一种包含特异性结合gprc5d和cd3的双特异性抗体的药物组合物
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025094085A1 (en) 2023-10-31 2025-05-08 Janssen Biotech, Inc. Combination regimens for treating multiple myeloma
US20250188163A1 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. Gprc5d antibodies with enhanced effector function and uses thereof
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
CN117843788B (zh) * 2024-01-09 2025-02-11 四川大学 一种抗gprc5d的抗体及其多特异性抗体和相关应用
CN118108846B (zh) * 2024-02-04 2024-11-26 四川大学华西医院 靶向GPRC5D同种异体CAR-γδT细胞的制备及应用
WO2025194478A1 (en) * 2024-03-22 2025-09-25 Biofront Ltd Antibodies binding to cd3 and gprc5d, and uses thereof
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025259877A1 (en) * 2024-06-12 2025-12-18 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting gprc5d and cd3 and methods of use thereof
WO2026001931A1 (zh) * 2024-06-24 2026-01-02 南京蓬勃生物科技有限公司 Gprc5d结合分子及其用途
US20260014252A1 (en) 2024-07-11 2026-01-15 Regeneron Pharmaceuticals, Inc. GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1468694A1 (en) 2001-12-27 2004-10-20 Sumitomo Pharmaceuticals Company, Limited Remedies for anorexia or lifestyle-related diseases and method of screening the same
WO2005086568A2 (en) 2004-01-26 2005-09-22 Morphosys Ag Anti-icam-1 human antibodies and uses thereof
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
EP2155788B1 (en) 2007-04-03 2012-06-27 Micromet AG Cross-species-specific bispecific binders
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
RS58217B1 (sr) 2007-04-03 2019-03-29 Amgen Res Munich Gmbh Interspecijski specifičan vezujući domen
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
CN102099378B (zh) * 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
PL2352763T5 (pl) 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
DK2356153T3 (en) 2008-10-01 2016-07-04 Amgen Res Munich Gmbh Bispecific single CHAIN ​​PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
EP3128048B1 (en) 2008-10-31 2018-11-28 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
RU2562700C2 (ru) 2009-02-12 2015-09-10 Янссен Байотек, Инк. Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
CN103842383B (zh) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
FR2994803B1 (fr) 2012-08-30 2016-02-26 Oreal Modulation de la forme des fibres keratiniques
NZ708182A (en) 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX385936B (es) 2014-03-28 2025-03-11 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3.
CA2959171C (en) 2014-09-05 2023-11-14 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
UA122212C2 (uk) 2014-09-09 2020-10-12 Янссен Байотек, Інк. Вид комбінованої терапії з застосуванням антитіла до cd38
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
KR20230159637A (ko) * 2014-12-05 2023-11-21 메모리얼 슬로안 케터링 캔서 센터 G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
EA201890513A1 (ru) 2015-08-17 2018-11-30 Янссен Фармацевтика Нв Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение
KR20180072820A (ko) 2015-11-02 2018-06-29 얀센 파마슈티카 엔.브이. 항-il1rap 항체, il1rap 및 cd3과 결합하는 이중특이성 항원 결합 분자, 및 그의 용도
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
TW201837174A (zh) 2017-02-07 2018-10-16 日商第一三共股份有限公司 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
US11970542B2 (en) 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies
CA3194796A1 (en) 2020-09-16 2022-03-24 Janssen Biotech, Inc. Methods for treating multiple myeloma
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物

Also Published As

Publication number Publication date
AR133827A2 (es) 2025-11-05
CL2019000146A1 (es) 2019-04-26
LTPA2026501I1 (es) 2026-01-26
CN109715667A (zh) 2019-05-03
UY40768A (es) 2024-06-28
TW201809005A (zh) 2018-03-16
IL264334B2 (en) 2024-05-01
KR20230128409A (ko) 2023-09-04
SG11201900468YA (en) 2019-02-27
CN109715667B (zh) 2022-12-30
AR133826A2 (es) 2025-11-05
CO2019001114A2 (es) 2019-02-19
US11884722B2 (en) 2024-01-30
EP3487882A2 (en) 2019-05-29
CL2024001016A1 (es) 2024-10-04
HRP20251181T1 (hr) 2025-12-05
TWI781108B (zh) 2022-10-21
HUE073077T2 (hu) 2025-12-28
KR20250073578A (ko) 2025-05-27
JP2023011774A (ja) 2023-01-24
CL2024001015A1 (es) 2024-10-04
CR20190025A (es) 2019-03-14
MX2019000825A (es) 2019-09-04
LT3487882T (lt) 2025-10-10
AU2017299673A1 (en) 2019-02-07
JP7292200B2 (ja) 2023-06-16
US10562968B2 (en) 2020-02-18
NZ790480A (en) 2025-12-19
RS67235B1 (sr) 2025-10-31
AU2024205021A1 (en) 2024-08-15
CL2024000444A1 (es) 2024-08-23
US11685777B2 (en) 2023-06-27
PE20190392A1 (es) 2019-03-13
IL264334A (en) 2019-02-28
CA3031472A1 (en) 2018-01-25
EP4643953A2 (en) 2025-11-05
UY40769A (es) 2024-06-28
PH12019500152A1 (en) 2019-10-14
AR109499A1 (es) 2018-12-19
ES3042078T3 (en) 2025-11-18
KR102811945B1 (ko) 2025-05-23
KR20190028534A (ko) 2019-03-18
EA201990346A1 (ru) 2019-06-28
JP7469432B2 (ja) 2024-04-16
IL298277A (en) 2023-01-01
MA45712B1 (fr) 2025-09-30
CN116333133A (zh) 2023-06-27
ZA201901066B (en) 2020-10-28
FI3487882T3 (fi) 2025-09-25
AR132097A2 (es) 2025-05-28
PE20240884A1 (es) 2024-04-24
UY40770A (es) 2024-06-28
SI3487882T1 (sl) 2025-11-28
BR112019001055A2 (pt) 2019-10-01
SMT202500356T1 (it) 2025-11-10
MX2023006449A (es) 2023-06-15
PT3487882T (pt) 2025-10-13
WO2018017786A3 (en) 2018-03-01
ECSP19012075A (es) 2019-02-28
JP2019527061A (ja) 2019-09-26
MA45712A (fr) 2019-05-29
JP2024054176A (ja) 2024-04-16
IN201917002488A (es) 2019-04-26
WO2018017786A2 (en) 2018-01-25
US20180037651A1 (en) 2018-02-08
UY40672A (es) 2024-04-30
US20240343796A1 (en) 2024-10-17
MX2024001615A (es) 2024-02-28
IL264334B1 (en) 2024-01-01
UY37340A (es) 2018-01-31
FIC20265003I1 (fi) 2026-01-12
EP3487882B1 (en) 2025-07-16
PL3487882T3 (pl) 2025-11-17
KR102572091B1 (ko) 2023-08-31
DK3487882T3 (da) 2025-09-22
NZ750152A (en) 2025-12-19
AU2017299673B2 (en) 2024-08-01
US20230227548A1 (en) 2023-07-20
US20230084967A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
NI201900005A (es) Anticuerpos anti-gprc5d, molã‰culas de uniã“n a antãgeno bispecãfico que unen a gprc5d y cd3, y sus usos
NI201800057A (es) Anticuerpos anti-il1rap, moléculas de unión de antígeno biespecíficas que se unen a il1rap y cd3, y sus usos.
ECSP18019568A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos
NI201700025A (es) Agentes de unión a cd123 y usos de estos.